Article info
PDFResearch ethics
Phase 1 oncology trials and informed consent
- Correspondence to Dr Franklin G Miller, Warren G. Magnuson Clinical Center, National Institutes of Health, Building 10, Room 1C118, Bethesda, MD 208921156, USA; fmiller{at}nih.gov
Citation
Phase 1 oncology trials and informed consent
Publication history
- Received June 1, 2012
- Revised October 2, 2012
- Accepted October 24, 2012
- First published November 17, 2012.
Online issue publication
April 27, 2016
Article Versions
- Previous version (27 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Two concepts of therapeutic optimism
- Unrealistic optimism and the ethics of phase I cancer research
- Informed consent for early-phase clinical trials: therapeutic misestimation, unrealistic optimism and appreciation
- Phase I oncology trials: why the therapeutic misconception will not go away
- Therapeutic appropriation: a new concept in the ethics of clinical research
- Perceptions of control and unrealistic optimism in early-phase cancer trials
- Phase I cancer trials: a qualitative study of specialist palliative care
- Living with Crohn’s disease: an exploratory cross-sectional qualitative study into decision-making and expectations in relation to autologous haematopoietic stem cell treatment (the DECIDES study)
- Faith, Hope And (No) Clarity
- Therapeutic optimism in the consent forms of phase 1 gene transfer trials: an empirical analysis